Gebro Pharma Laboratories, a CataloniaBio & HealthTech member, recently signed an agreement with Novartis Farmacéutica, S.A. with Novartis Farmacéutica, S.A. under which, as of June 2022, it will be responsible for the national distribution of the Swiss company's drugs Xiliarx® and Icandra®. Both drugs belong to the category of oral antidiabetics for the treatment of type 2 diabetes in adults.
With the signing of this agreement, Gebro Pharma and Novartis Farmacéutica, S.A. consolidate an alliance that began in 2015 with the signing of an agreement for the marketing of three products for patients in the respiratory therapy area.
According to Ivet Vall, Director of Business Development & Innovation at Gebro Pharma, "with this agreement we consolidate our relationship with Novartis Farmacéutica, S.A. and for the first time we are at the service of diabetic patients, for whom we will guarantee optimum distribution of these medicines, in line with our aim of improving people's health and lives".
Comments